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Edited by Beat ImhofAbstract MIF was recently redeﬁned as an inﬂammatory cyto-
kine, which functions as a critical mediator of diseases such as
septic shock, rheumatoid arthritis, atherosclerosis, and cancer.
MIF also regulates wound healing processes. Given that ﬁbro-
blast migration is a central event in wound healing and that
MIF was recently demonstrated to promote leukocyte migration
through an interaction with G-protein-coupled receptors, we
investigated the eﬀect of MIF on ﬁbroblast migration in wounded
monolayers in vitro. Transient but not permanent exposure of
primary mouse or human ﬁbroblasts with MIF signiﬁcantly pro-
moted wound closure, a response that encompassed both a
proliferative and a pro-migratory component. Importantly,
MIF-induced ﬁbroblast activation was accompanied by an induc-
tion of calcium signalling, whereas chronic exposure with MIF
down-regulated the calcium transient, suggesting receptor desen-
sitization as the underlying mechanism.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: MIF; Wound healing; Migration; Inﬂammation;
Fibroblast; CXCR41. Introduction
Macrophage migration inhibitory factor (MIF) is one of the
ﬁrst cytokines discovered [1]. MIF was initially deﬁned as a T-
cell factor which inhibited the random migration of macro-
phages. Thus, MIF activity was implicated in ‘‘negative’’
regulation of cell motility. More recently, MIF was redeﬁned
as a pleiotropic inﬂammatory cytokine with broad target cell
speciﬁcity that is secreted upon inﬂammatory stimulation, tis-
sue injury, and cellular stress by a variety of immune cells, butAbbreviations: CXCR, CXC chemokine receptor; GPCR, G-protein-
coupled receptor; HFDFs, human foreskin dermal ﬁbroblasts; MEFs,
mouse embryonic ﬁbroblasts; MIF, macrophage migration inhibitory
factor; rMIF, recombinant human MIF; wt, wild-type; wtMEFs, wild-
type MEFs
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doi:10.1016/j.febslet.2007.08.071also endothelial, pituitary, and some epithelial cells [1–3]. MIF
has been recognised as a critical mediator of acute and chronic
inﬂammatory diseases such as septic shock, Crohn’s disease,
rheumatoid arthritis, and atherosclerosis [1,4]. Furthermore,
MIF is overexpressed in numerous cancers, has been linked
to the development of colon cancer, and has been proposed
to constitute a molecular link between inﬂammation and can-
cer [5–7]. In a recent report, Hagemann et al. conclude that tu-
mor necrosis factor-a (TNF-a) induces tumour-associated
macrophages to secrete MIF, which serves to enhance the
invasive capacity of the tumour cells [8]. In line with these
observations, MIF was found to promote the migration of he-
patic carcinoma cells through the angiogenic factors interleu-
kin-8 (IL-8) and vascular endothelial growth factor (VEGF)
[9] and to stimulate the migration of microvascular endothelial
cells [10]. In elucidating the molecular mechanism underlying
MIF-induced leukocyte recruitment into atherogenic vessels,
Bernhagen et al. demonstrated that MIF triggers monocyte/
neutrophil and T-cell arrest and chemotaxis through interac-
tion with the chemokine receptors CXCR2 and CXCR4,
respectively [11,12]. MIF-induced CXCR receptor activity in-
volved the MIF binding protein CD74, Gia protein coupling,
calcium signalling, Src-type kinase and integrin activation
[11]. Together, these studies show that MIF promotes pro-
migratory processes both indirectly through stimulating the
release of other migratory factors and directly through an
interaction with CXCR2/4.
MIF plays a key role in the aging-related attenuation of the
wound healing response as demonstrated by its upregulation in
wounds of estrogen-deﬁcient mice [13]. The excessive inﬂam-
mation and delayed-healing phenotype associated with re-
duced estrogen was reversed in MIF/ mice. This was due
to an estrogen-mediated decrease in MIF production by acti-
vated macrophages and more generally by an inhibition of
the local inﬂammatory response by downregulating MIF
[13]. Hardman et al. proﬁled changes in gene expression within
the wounds of mice that were wild-type or null for MIF in the
presence or absence of estrogen, conﬁrming MIF as a key
player in wound healing, regulating many repair/inﬂamma-
tion-associated genes [14]. These observations went along with
increased serum and wound levels of MIF over age and a
down-regulation of MIF by estrogen in vivo. While these stud-
ies have implicated MIF in the attenuation of wound healing
in the absence of estrogen, Abe et al. noticed that a biphasic
induction of MIF during wound healing of rat skin injuredblished by Elsevier B.V. All rights reserved.
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on the wound healing process of skin tissue [15]. When com-
paring excision wounds from the dorsal skin of MIF/ mice
with those of wild-type animals (MIF+/+), healing was signiﬁ-
cantly delayed in MIF/ mice, suggesting that MIF is crucial
in accelerating cutaneous wound healing [16]. Thus, MIF has
been proposed to both promote and attenuate wound healing
processes. These seemingly contradictory data might be
reconcile if one considers that the wound healing process is
complex, consisting of four distinct phases. These are the
homeostasis phase (immediately upon injury; mainly charac-
terized by rapid thrombus formation), the inﬂammation phase
(up to 4–6 days after injury; leading to the recruitment of
inﬂammatory cells), the migration phase (up to 6–8 days upon
injury; mostly featuring the accumulation of ﬁbroblasts and
the production of extracellular matrix structures), and the
remodelling phase (day 8 through 1 year after injury) [17,18].
The migration phase is sometimes termed proliferation phase
(day 4 through 14 after injury) [17]. Although the precise role
of MIF in these phases has not yet been addressed, due to its
well-known role as a key regulator of inﬂammation and mod-
ulator of cell migration and proliferation, MIF would be pre-
dicted to be functionally involved in at least two of the four
phases.
To address the mechanism(s) through which MIF may par-
ticipate in the migration (proliferation) phase, we have investi-
gated the eﬀect of exogenously added recombinant MIF
(rMIF) on the motility of mouse embryonic ﬁbroblasts
(MEFs) in an in vitro model of artiﬁcially wounded monolay-
ers (‘scrape wounds’) following both transient and permanent
(‘chronic’) exposure with rMIF. Both MEFs from mice genet-
ically deﬁcient for MIF (MIF/ MEFs) and wild-type mice
were studied. Given the established eﬀect of MIF on prolifer-
ative responses, wound closure in the presence versus absence
of mitomycin C was compared and the proliferative share was
assessed by Ki67 staining. Migration-associated MIF-stimu-
lated Gia-protein-coupled receptor (GPCR) activity was eval-
uated by measuring calcium transients. Finally, to probe for
the physiological eﬀect in the healing of skin wounds, primary
human dermal ﬁbroblasts were included in the study.2. Materials and methods
2.1. Recombinant MIF and chemicals
Recombinant human MIF (rMIF) was prepared as described previ-
ously [19,20]. rMIF was >98% pure as analysed by SDS–PAGE elec-
trophoresis in combination with silver staining and was biologically
active as determined by its anti-apoptotic and MAPK-stimulatory
activity (data not shown and [21,22]). The rMIF preparation contained
negligible concentrations of endotoxin (<10 pg endotoxin/lg MIF) as
measured by Limulus Amebocyte Lysate (LAL, QCL-1000) assay
(Cambrex, Verviers, Belgium). Mitomycin C, miscellaneous chemicals
and salts were from Sigma-Aldrich Chemicals (Taufkirchen, Ger-
many). All reagents were of the highest grade commercially available.
2.2. Cells and cell culture
Cell culture reagents were from Invitrogen (Karlsruhe, Germany),
unless stated otherwise. Primary mouse embryonic ﬁbroblasts
(MIF/MEFs and MIF+/+ or wild-type MEFs) were prepared from
MIF/ or wild-type mice (both C57BL/6 background) as described
[23]. MEFs were cultured in Dulbecco’s modiﬁed Eagle medium
(DMEM), containing 10% FCS, 1% penicillin–streptomycin, and
5 mM L-glutamine. Primary MEFs were used at passage 3–6. All cell
culture experiments were performed at 37 C in a humidiﬁed incubator
with 5% CO2.Human foreskin dermal ﬁbroblasts (HFDFs) were isolated and cul-
tured from human foreskin of two diﬀerent donors essentially as de-
scribed previously [24]. Brieﬂy, normal ﬁbroblasts were obtained
from foreskin specimen. After excision, the specimens were washed
three times in sterile phosphate-buﬀered saline (PBS; Invitrogen, Pais-
ley, UK) containing antibiotics (penicillin–streptomycin; Invitrogen)
and antimycotics (amphotericin B; PAA, Pasching, Austria), and di-
gested in dispase solution (50 caseinolytic U/mL; Collaborative, Bed-
ford, MA, USA) for 20 h at 4 C and subsequently for 2 h at 37 C.
The epidermis was removed and the dermis was digested in collagenase
I (100 U/ml; Sigma, Deisenhofen, Germany) at 37 C for 3 h. Remain-
ing ﬁbroblasts were seeded into petridishes with DMEM containing
high glucose and L-glutamine (Invitrogen), and 10% FCS (Biochrom,
Berlin, Germany). Cells were cultivated in a CO2 incubator at 37 C
in a humidiﬁed atmosphere with 5% CO2 until reaching the state of
early conﬂuence.2.3. In vitro ‘wound healing’ assay
MIF/ and MIF+/+MEFs were plated in 6 cm culture plates (Cell-
star, Greiner, Frickenhausen, Germany) and allowed to proliferate un-
til 90% conﬂuency was reached (DMEM medium containing 10%
FCS, 1% penicillin–streptomycin). Some cell incubations were treated
with 10 lM mitomycin C or control solvent for 2 h prior to assessing
their migration behavior. For subsequent treatment of cells with rMIF,
FCS content was reduced to 0.5% and rMIF added either transiently
or permanently, or cells left untreated. Incubations treated with phos-
phate buﬀer instead of rMIF were designated ‘‘N’’, cells transiently
treated with 50 ng/mL rMIF for 2 h were termed ‘‘2 h’’, and the group
of cells permanently incubated with 50 ng/mL rMIF was designated
‘‘P’’. HFDFs were plated and treated following the same scheme.
Cell cultures were ‘wounded’ (‘scraped’) (time point t = 0 h; t = 0)
with a rubber policeman as described previously [25]. To measure
the migratory response of the cells into the scrape wounds, microscopic
photographs were taken 0 and 24 h after injury. For microscopic
examination of the migration response at the indicated time intervals,
cells were placed on the microscope table, examined, and returned to
the incubator immediately following the measurement. The migration
distances were then deduced from the comparison of the 0 and 24 h
photographs and expressed in arbitrary distance units.
2.4. Assessment of ﬁbroblast proliferation by Ki67 staining
Proliferating HFDFs in the ﬁrst and second passage were used. Der-
mal ﬁbroblasts were cultured in chamber slides until they reached 90%
conﬂuence, the medium was changed to 0.5% FCS, and the cells incu-
bated for another 20 h prior to the addition of rMIF. A scratch wound
was produced in all chambers using a yellow Gilson pipette tip. Cells
were incubated with or without 50 ng/mL rMIF for up to 24 h at
37 C in a 5% CO2 incubator. Photographic documentation and mea-
surement of the scratch expanse was performed at diﬀerent time points
using a DMIL microscope (Leica, Wetzlar, Germany). Scrape wounds
had a width of approximately 1000 lm at t = 0 h. Treatment with 10%
FCS served as a positive control with which full ‘wound closure’ was
achieved after 24 h.
In parallel, chamber slides were harvested after 10 and 20 h of incu-
bation for immunostaining of Ki67. For this analysis, ﬁbroblasts were
washed with PBS, ﬁxed with methanol for 10 min at 20 C, and air-
dried as described [26]. Brieﬂy, chamber slides were stained using an
antibody against human Ki67 (1:50 dilution; Dako, Glostrup, Den-
mark) and a Cy3-labelled secondary antibody. Ki67 is speciﬁcally ex-
pressed in the nuclei of cycling but not non-cycling cells and staining
appears as nucleoli-speciﬁc immunoreactivity. Slides were counter-
stained with DAPI (1:500 dilution, Applichem Darmstadt, Germany)
to visualise all cell nuclei in the scrape area.
2.5. Calcium signalling
MIF/MEFs (106 cells/mL) were labelled with the calcium-sensitive
dye Fluo-4AM (Molecular Probes, Eugene, OR) at 0.9 lM in assay
buﬀer (130 mM NaCl, 4.6 mM KCl, 1 mM CaCl2, 5 mM glucose,
20 mM HEPES, pH 7.4) for 45 min at 37 C. To control for cellular
dye loading eﬃciency, cells were labelled in parallel with SNARF-1
at 0.9 lM. After washing, cells were resuspended at 2 · 106 cells/mL
and kept at 37 C. Immediately after the addition of the ﬁrst stimulus
(rMIF at 250 ng/mL), the mean ﬂuorescence intensity (MFI) as a mea-
sure of the cytosolic Ca2+ concentration was monitored for 120 s using
4736 M. Dewor et al. / FEBS Letters 581 (2007) 4734–4742the BD FACSAria System (BD Biosciences, San Jose, CA). The sec-
ond stimulus (rMIF at 250 ng/mL) was added at 130 s or after 2 h,
and MFI was monitored for another 120 s. Experiments were analyzed
via FlowJo Software (Tree Star, OR).
2.6. Statistical analysis
Statistical signiﬁcance between two groups of data was evaluated by
using Student’s t-test. P values below 0.05 were considered statistically
signiﬁcant. Signiﬁcance between two treatment groups is indicated by
*, ** or ***, with * referring to P value of <0.05, ** representing a P
value of <0.01, and *** indicating a P value of <0.005.3. Results
3.1. Short-term treatment with MIF promotes the migration of
wild-type and MIF-deﬁcient mouse embryonic ﬁbroblasts in
scrape-wounded monolayers
To investigate whether MIF modulates ﬁbroblast migration
during wound healing processes, the eﬀect of exogenously
added rMIF on the motility of MEFs was studied in an
in vitro model of artiﬁcially wounded monolayers (‘scrapeA B
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Fig. 1. Short-term treatment with MIF promotes the migration of wild-typ
monolayers. (A,B) Wild-type MEF monolayers were wounded by scrapin
Microscopic photographs of representative migration experiments at t = 0 h
scraping and following addition of 50 ng/mL rMIF for 2 h. (B) Quantitative a
treated with exogenous rMIF (control, N), treated with 50 ng/mL rMIF for
migration period (P). Data are mean values ± S.D. of n = 6 independent exp
used in the scrape-wound assay. Data are mean values ± S.D. of n = 5 i
diﬀerences (**, P < 0.01; ***, P < 0.005).wounds’). The apparent migration of ﬁbroblasts into scraped
spaces may both encompass a migratory and a proliferative
component. As MIF has been demonstrated to diﬀerentially
inﬂuence ERK1/2-MAPK-driven cell proliferation processes
under transient versus permanent conditions [21,27], the po-
tential migratory eﬀect of MIF was studied after both transient
and permanent exposure of ﬁbroblasts to MIF. Initially, wild-
type MEFs constitutively expressing MIF at appreciable levels
were used.
When transiently treated with 50 ng/mL rMIF for 2 h, a
marked migratory response was observed in scraped MEF
monolayers (Fig. 1). To verify that this eﬀect was MIF-speciﬁc,
migration behaviour in the presence of transiently added rMIF
(‘‘2 h’’) was compared with that in the absence of rMIF (‘‘N’’)
(Fig. 1B). Treatment with exogenous rMIF led to a signiﬁcant
MIF-dependent increase in ﬁbroblast motility (P < 0.01).
Thus, MIF was able to promote ﬁbroblast migration in
in vitro experiments mimicking wound healing situations.
Moreover, this eﬀect was only observed when MEFs were
transiently but not permanently treated with rMIF, as theN 2h P
** ***
Migration conditions
Wildtype MEFs
Migration conditions
N 2h P
*** ***
MIF—/— MEFs
e and MIF-deﬁcient mouse embryonic ﬁbroblasts in scrape-wounded
g and migration/wound closure followed microscopically over 24 h.
(upper panel) were compared with those at t = 24 h (lower panel) after
nalysis of the 24 h-migration distances of MEFs which were either not
2 h (2 h), or permanently treated with 50 ng/mL MIF over the entire
eriments. (C) As in (A,B) except that MIF/ MEF monolayers were
ndependent experiments. Asterisks indicate statistical signiﬁcance of
M. Dewor et al. / FEBS Letters 581 (2007) 4734–4742 4737migration response was blunted when wounded MEFs were
exposed to rMIF for the entire observation time of 24 h
(‘‘P’’) (Fig. 1B). Migration under such conditions was not only
signiﬁcantly decreased compared to the ‘‘2 h’’ treatment
(P < 0.005), but there was also a tendency, which however
did not reach statistical signiﬁcance, that permanent exposure
to rMIF led to a slight inhibitory eﬀect compared to migration
in the absence of rMIF. This could indicate that a baseline
migration response is mediated by a low-eﬃciency constitu-
tive-like release of MIF from the wtMEFs, consistent with ear-
lier reports on autocrine eﬀects of MIF [27–29].A
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Fig. 2. The MIF-stimulated ‘wound-closure’ response encompasses a true m
dermal ﬁbroblasts. (A,B) MIF/MEF monolayers were pretreated with
migration followed microscopically over 24 h. (A) Microscopic photographs
compared with those at t = 24 h (lower panel) after scraping and following ad
migration distances of MIF/MEFs which were either not treated with exog
permanently treated with 50 ng/mL MIF over the entire migration period (P)
As in (A,B) except that primary human foreskin dermal ﬁbroblasts (HFD
experiments. Asterisks indicate statistical signiﬁcance of diﬀerences (*, P < 0The MIF-induced migratory response in ‘wounded’ wtMEF
monolayers was signiﬁcant but of moderate strength (increase
of 50%). Given our observation that permanent MIF treat-
ment abolished this eﬀect, we surmised that desensitization
may occur when exposure to MIF is long-lasting as by perma-
nent addition of exogenous MIF or due to autocrine eﬀects. To
address this issue, scrape assays were performed with MEFs
derived from mice rendered genetically deﬁcient for MIF
(MIF/). Fig. 1C demonstrates that in scratched MIF/MEF
monolayers, the migratory eﬀect induced by 2 h treatment with
exogenous MIF was much more pronounced than on cells withs + mitomycin C
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igratory eﬀect and is also observed in monolayers of primary human
the proliferation inhibitor mitomycin C, wounded by scraping, and
of representative migration experiments at t = 0 h (upper panel) were
dition of 50 ng/mL rMIF for 2 h. (B) Quantitative analysis of the 24 h-
enous rMIF (control, N), treated with 50 ng/mL rMIF for 2 h (2 h), or
. Data are mean values ± S.D. of n = 4 independent experiments. (C,D)
Fs) were used. Data are mean values ± S.D. of n = 6 independent
.05; ***, P < 0.005).
A HFDFs
Control + MIF
ScratchScratch
B HFDFs
Anti-Ki67 DAPI
MIF
4738 M. Dewor et al. / FEBS Letters 581 (2007) 4734–4742a MIF-positive background (i.e. wtMEFs) (220% increase;
P < 0.01 compared to buﬀer-treated cells). As in the wtMEFs,
the diﬀerence between transient and permanent treatment was
much stronger as well (>300%; P < 0.005). Thus, MIF has a
marked eﬀect on the closure of scraped cell layers, but only
when transiently added for a short time interval on ﬁbroblasts
not previously stimulated by MIF.
3.2. The MIF-stimulated ‘wound-closure’ response encompasses
a true migratory eﬀect and is also observed for primary
human dermal ﬁbroblasts
The migration experiments were performed in the absence of
a proliferation-blocking agent. Thus, it is likely that the MIF-
induced migratory response in the scraped monolayers may re-
ﬂect the result of both proliferative and migratory eﬀects of
MIF, adding up to an observed overall ‘migration’ or
‘wound-closure’ eﬀect. To distinguish between the individual
components contributing to the overall eﬀect and to verify that
MIF is able to stimulate a net pro-migratory response in the
scraping assay, ﬁbroblast proliferation was blocked by pre-
incubation with mitomycin C. Initial scouting experiments ver-
iﬁed that 10 lM mitomycin C led to a complete inhibition of
MEF proliferation (data not shown).
Wounded MIF/MEF monolayers pre-treated with mito-
mycin C for 2 h were analysed for their migratory response
over a 24 h time interval as before. Of note, despite the pres-
ence of a proliferation blocker, treatment of cells with rMIF
promoted migration and scratch closure (Fig. 2A). As before,
the eﬀect was signiﬁcant, and was only observed upon expo-
sure to transient, short term treatment with rMIF, but not
when rMIF was added permanently (P < 0.05 compared to un-
treated control and P < 0.05 compared to permanent stimula-
tion) (Fig. 2B). Although not reaching statistical signiﬁcance,
permanent treatment of monolayers with rMIF showed a ten-
dency in leading to a net reduction of the migratory response,
i.e. to an apparent migration-inhibitory eﬀect that was reminis-
cent of a desensitization response. As expected due to the
experimental ablation of the proliferative arm of the response
by the anti-proliferative chemical agent, the relative increase in
MIF-induced ‘wound-closure’ was smaller than that seen in
the absence of mitomycin C (35%; compare Fig. 2B with
Fig. 1C).Table 1
Scratch-induced wound-closure assay in human dermal ﬁbroblasts
Width of
scratch at
0 h (lm)
Width of
scratch at
7 h (lm)
Closure
rate (%)
Width of
scratch at
24 h (lm)
Closure
rate (%)
Donor 1
10% FCS 946 797 15.8 0 (closed) 100
0.5% FCS 1071 1004 6.3 531 50.5
Buﬀer 1231 1083 11 572 52.7
rMIF
(50 ng/mL)
1188 937 20.1 170* 84.2
Donor 2
10% FCS 1059 813 23.2 203* 88.5
0.5% FCS 1060 974 8 431 58.8
Buﬀer 1091 898 17.7 452 58.5
rMIF
(50 ng/mL)
1039 791 23.9 115* 89
Scratch widths are mean values of two experiments.
*Scratch was partially closed.To investigate whether the observed migratory eﬀect of MIF
was limited to wounded monolayers of embryonic ﬁbroblasts
or to mouse cells, human foreskin dermal ﬁbroblasts (HFDFs)
were applied. The migration behaviour in scraped monolayers
of HFDFs pre-treated with mitomycin C was analysed follow-
ing 2 h stimulation with 50 ng/mL rMIF, permanent stimula-
tion with rMIF, or addition of control buﬀer, as before. In
these initial studies that were performed in the presence of
mitomycin C, wound closure was measured after a 24 h time
interval. Short-term treatment with rMIF for 2 h led to a sig-
niﬁcant increase in the migration response both in comparison
with untreated cells (P < 0.005) and permanent MIF exposure
(P < 0.05) (Fig. 2C and D). As HFDFs represent a more phys-
iological ‘wound healing’ model, these data conﬁrm the notion
that MIF may play an important role in the migration phase of
wound healing. Together, we conclude that short-term treat-Control
Fig. 3. The MIF-stimulated ‘wound-closure’ response in primary
human dermal ﬁbroblasts encompasses a proliferative eﬀect. Primary
human foreskin dermal ﬁbroblast (HFDF) monolayers were wounded
by scraping and proliferation/wound closure followed microscopically
over 20 h. Microscopic photographs of representative experiments are
shown comparing the eﬀect of a 2 h incubation with 50 ng/mL rMIF
with that of control phosphate buﬀer. (A) Overview of the scratch area
as indicated. Cells were stained with DAPI. Note that in the presence
of rMIF, the wound is almost fully closed whereas spontaneous
ﬁbroblast proliferation/migration only leads to a slight narrowing of
the scratch area. For quantiﬁcation of these experiments, see Table 1.
(B) As in (A) except that cells were additionally stained with Ki67,
which speciﬁcally stains cycling/proliferating cells. Treatment of
monolayers with rMIF for 2 h (upper panel) results in the appearance
of numerous Ki67+ cells in the scrape area, whereas almost no Ki67+
cells are seen in control buﬀer-treated monolayers. The data shown are
representative of two independently performed experiments with
HFDFs from two donors each.
M. Dewor et al. / FEBS Letters 581 (2007) 4734–4742 4739ment of artiﬁcially wounded MEF or HFDF monolayers with
rMIF led to a migratory response of these ﬁbroblast cells as
part of the ‘wound healing’ process. The data also implied that
MIF enhances a proliferative response when the ﬁbroblasts are
proliferation-competent, as the migratory response in the pres-
ence of mitomycin C was less pronounced than in the absence
of any proliferation block.
3.3. The MIF-stimulated ‘wound-closure’ response in primary
human dermal ﬁbroblasts encompasses a proliferative eﬀect
The application of mitomycin C indirectly showed that
MIF also modulated ﬁbroblast proliferation. To directly test
whether MIF-induced ‘scratch wound closure’ included a
proliferation-activating eﬀect of MIF, scratched MIF-treated
HFDF monolayers in the absence of mitomycin C were
analysed further. These experiments also included a more de-
tailed quantiﬁcation of the MIF-induced scratch wound-clo-
sure eﬀect. Quantiﬁcation was performed by measuring the
width of the scratch in the MIF- vs. buﬀer vs. FCS-treated
monolayers at various time intervals following DAPI staining
of cell nuclei. HFDFs from two diﬀerent donors were ana-
lysed.
The width of the scratch at 0 h was 1000 lm in each spec-
imen and was considered 0% closure, with widths ranging from
946 to 1231 lm. Full closure of the scratch (0 lm) was ob-
served by treatment of cells with 10% FCS for 24 h for one do-
nor (Table 1). Addition of recombinant exogenous MIF for
2 h led to marked scratch closure (Fig. 3A). The MIF-inducedA
Fl
uo
-4
/S
N
A
R
F-
1
Time (sec)
MIF MIF
MIF—/— MEFs
0 60 120 180 240
0.75
1.00
1.25
B
2
0 20 40 60 80 100 120
0.75
1.00
1.25
Time (sec)
Fl
uo
-4
/S
N
A
R
F-
1 MIF
MIF—/— MEFs
Fig. 4. MIF triggers rapid calcium transients in mouse embryonic ﬁbroblast
exposure to MIF. (A) Fluo-4- and SNARF-1-stained MIF/MEF were treat
ﬂow cytometry (ﬁrst arrow). Cells were desensitized thereafter, as re-stimul
response. (B) Desensitization lasts for a prolonged time period in the perm
stimulation with rMIF was performed 2 h and 2 min after the initial calcium
calcium measurements shown are representative of 2–3 independent experimeﬀect represented a relative closure rate of 86.6 ± 2.4% and was
speciﬁc, as buﬀer or 0.5% FCS alone only led to spontaneous
closure rates of 54.7 ± 4.2% or 55.6 ± 2.9%, respectively (Table
1). Thus, MIF potently promotes closure of scratch wounds of
human dermal ﬁbroblasts.
As no mitomycin C was added to the cells, the MIF-induced
closure eﬀect likely encompassed both proliferation and migra-
tion processes. To directly evaluate the eﬀect of MIF on prolif-
eration following ‘wounding’, we performed Ki67 stains of the
ﬁbroblasts in the scratch region, a staining method speciﬁcally
detecting cycling cells. Fig. 3B shows that stimulation with
rMIF led to a marked increase in Ki67+ cells, while DAPI
counterstaining conﬁrmed that migration also contributed to
MIF-induced wound closure. Quantitative analysis (ratio:
Ki67+/DAPI-positive cells; 5 ﬁelds each; 2 time points) re-
vealed that 62.3 ± 12.5% of the DAPI-positive cells were
Ki67+, indicating that proliferation contributed by roughly
two-third to the observed apparent wound-closure eﬀect, while
migration accounted for approximately one-third.
3.4. MIF-stimulated calcium signalling is down-regulated by
chronic exposure to MIF
We recently demonstrated that MIF binds to CXCR2 and
CXCR4 and promotes the chemotactic migration of leuko-
cytes through a GPCR-mediated receptor pathway involving
CD74 and calcium signalling [11]. Fibroblasts express low
but measurable levels of CXCR4 and CD74 as evidenced by
ﬂow cytometry analysis (data not shown) and we thereforeTime (sec)
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calcium signalling. In fact, treatment of MIF/MEFs with
rMIF induced a rapid calcium transient within a few seconds
that also desensitized ﬁbroblasts for a subsequent stimulation
with rMIF after 120 s (Fig. 4A), comparable to what had been
previously observed by us in leukocytes [11]. To begin to ex-
plore the mechanism underlying the inhibition of ﬁbroblast-in-
duced scrape wound-closure under chronic exposure to MIF,
MIF-induced calcium responsiveness was then examined
over a more ‘chronic’ time period. A ﬁbroblast calcium signal
was triggered as before by addition of rMIF, but the MIF-con-
taining medium was not removed. When the cells were re-chal-
lenged with rMIF 2 h and 2 min after the initial MIF-triggered
calcium signal had declined, mimicking chronic exposure to
MIF in the scratch wound monolayers, no anew rise in calcium
was measurable (Fig. 4B). This indicated that prolonged expo-
sure of ﬁbroblasts to exogenous MIF leads to a desensitization
of MIF receptor activity and calcium signalling with a subse-
quent inhibition of ﬁbroblast-mediated scrape wound
closure.4. Discussion
Recent data have implicated MIF as a key regulator of
wound healing responses [13,14,16]. Depending on the model,
MIF inhibited or promoted wound healing. In mouse models
of estrogen-depletion, mimicking aging-related reductions of
estrogen levels in women, MIF was found up-regulated in
cutaneous wounds but functioned to attenuate wound healing
[13,14]. Estrogen-mediated down-regulation of MIF and pro-
tection from MIF-dependent inﬂammatory processes was re-
cently conﬁrmed in a model of colon inﬂammation [30]. On
the other hand, Abe and colleagues observed that an upregu-
lation of MIF in skin wounds of rats was accompanied by
an accelerating eﬀect of MIF on the wound healing process
of skin tissue [15]. On ﬁrst sight contradictory, these observa-
tions may suggest that MIF inﬂuences more than one mecha-
nism contributing to wound healing outcome. In fact, MIF is a
potent inﬂammatory mediator, suggesting that it could play a
role in the inﬂammation phase of wound healing, in line with
the ﬁndings by Ashcroft and colleagues [13]. MIF activates
matrix-degrading enzymes such as MMP-1, -9, and -13 [31–
34] and contributes to the mobilization of the extracellular ma-
trix in in vivo wound situations [14], supporting the notion that
overexpression of MIF in the inﬂammation phase encompasses
a matrix-turnover function. Of note, recent ﬁndings suggest
that MIF, contrary to its historic name, promotes the chemo-
tactic recruitment of inﬂammatory leukocytes into sites of in-
jury such as atherogenic arteries or the inﬂamed
microvasculature [11,35] and can activate the migration of
smooth muscle cells [36]. Together this would suggest that
MIF, along with cytokines such as PDGF or VEGF, could
play an important role in the early inﬂammation phase of
wound healing.
While ﬁbroblast recruitment occurs to only a smaller extent
in the inﬂammation phase, pronounced pro-migratory and
proliferative responses of this cell type are induced in the
migration/proliferation phase. MIF has been observed to en-
hance the proliferation rate of several cell types including
ﬁbroblasts [1,27,37]. However, the eﬀect of MIF on ﬁbroblast
proliferation in wound situations has not been studied. Also, itis unknown whether stimulation of cell migration by MIF may
extend to ﬁbroblasts and could occur during wound healing
processes. We hypothesized that MIF promotes ﬁbroblast pro-
liferation and migration during the ‘migration phase’ of wound
healing. If true, this could mean that MIF participates in the
regulation of wound healing through two distinct mechanisms
in two diﬀerent phases of the process. To probe for this possi-
bility, we examined the eﬀect of MIF on wound closure in a
well-deﬁned in vitro model of wounded ﬁbroblast monolayers.
Our data unanimously show that MIF promotes closure of
artiﬁcial scrape wounds in ﬁbroblast monolayers. This eﬀect
encompasses the expected pro-proliferative eﬀect on the ﬁbro-
blasts and our mitomycin C blockade experiments and Ki67
stains suggest that MIF-induced ﬁbroblast proliferation also
occurs in wound situations. Importantly, we also show that
MIF promotes ﬁbroblast migration upon wounding of the
monolayers. MIF-triggered ﬁbroblast migration and wound
closure only occurred, when cell layers were treated with rMIF
for short time intervals (2 h), but not upon sustained exposure.
This probably excludes the intermediate expression and release
of MIF-stimulated pro-migratory molecules such as chemo-
kines or migration-regulating cytokines. In fact, in light of re-
cent ﬁndings showing that MIF can not only indirectly activate
cell migration, but can directly trigger migration through inter-
action with CXCR chemokine receptors [11], our experiments
indicate that MIF enhances ﬁbroblast migration by direct
means.
MIF interacts as a non-cognate ligand with CXCR2 on
monocytes and neutrophils and with CXCR4 on T cells [11].
Surface-expressed CD74/invariant chain serves as a MIF bind-
ing site on B cells and some ﬁbroblast and tumour cell types
[37,38]. The ﬁbroblasts applied in our current study express
low but measurable levels of surface CXCR4 and CD74. While
no information is yet available about the role of the MIF/
CXCR4 axis in ﬁbroblast migration and wound healing,
CXCR4 in conjunction with its cognate ligand SDF-1
(CXCL12) have been implicated in ﬁbroblast migration, both
through chemotaxis and chemokinesis, as well as in dermal
wound healing responses [39,40]. GPCR-mediated cell migra-
tory responses lead to a rise in intracellular calcium as part of
the signalling process and MIF-triggered leukocyte migration
involves calcium signalling [11]. We show that MIF induces ra-
pid calcium signalling in mouse embryonic ﬁbroblasts and that
long-term treatment of ﬁbroblasts with MIF leads to desensiti-
zation of the calcium response, providing a mechanism for the
observed failure of ﬁbroblasts to migrate upon chronic expo-
sure to MIF. CXCR2 and CD74 form a receptor signalling
complex [11], but it is unknown whether CXCR4 can also en-
gage in a complex with CD74. It will thus be important in the
future to elucidate the precise contributions of these MIF
receptor proteins in MIF-mediated wound closure responses
both in vitro and in vivo, including the potential role of endog-
enously produced CXCL12 [40].
It may be speculated that MIF-mediated ﬁbroblast migra-
tion might be connected to the recently uncovered migratory
function of cytosolic p27Kip1 [41]. p27 is a cell cycle inhibitor
protein acting in the nucleus of all cells [42], but it has been rec-
ognized that growth factor signalling can result in nuclear ex-
port of Ser-10-phosphorylated p27 to the cytoplasm, where it
induces actin cytoskeletal rearrangement and subsequent
migration of cells. This ‘cell-scattering activity’ of p27 occurs
independently of its cell cycle arrest functions. MIF is known
M. Dewor et al. / FEBS Letters 581 (2007) 4734–4742 4741to interact with JAB1/CSN5 [20], a coactivator protein and
component of the COP9 signalosome that is involved in the
nuclear export of p27 [43,44].
The pro-migratory and wound-closure eﬀect of MIF was not
only observed in MEFs but also in primary HFDFs. HFDFs
represent an excellent model of wound healing processes and
disorders [24,45,46], suggesting that the observed eﬀects are
relevant for wound healing in vivo.
In summary, judging from the previous data by the Ashcroft
and Nishihira groups [13–16] in conjunction with our current
study, we predict that MIF contributes to both the inﬂamma-
tory and migration/proliferation phases of wound healing. We
propose the following chronology of events involving MIF.
Upon injury, it is likely that there will be a rapid and transient
release of preformed MIF from mesenchymal cells, contribut-
ing to leukocyte recruitment and, to a minor extent, recruit-
ment of ﬁbroblasts in the inﬂammatory phase, representing
necessary pro-healing processes. However, in situations and
models, where MIF is chronically expressed in the inﬂamma-
tion phase, such as under estrogen depletion, MIF, due to its
potent inﬂammatory potential, would serve to attenuate
wound healing progression, in which case therapeutic targeting
of MIF appears desirable. Interestingly, blocking the interac-
tion of the MIF receptor CXCR4 with its cognate ligand
CXCL12 has been shown to signiﬁcantly improve skin recov-
ery after burn wounds [40], implying that blockade of the
MIF/CXCR4 axis could be equally beneﬁcial. On the other
hand, MIF expression in the migration/proliferation phase
would contribute to improving wound healing outcome due
to its pro-proliferative activity and, as recognized for the ﬁrst
time in our current study, through its pro-migratory activity
on ﬁbroblasts. While these ﬁndings unravel a role of MIF in
the migration phase of wound healing and underpin the notion
that targeting MIF may represent a promising therapeutic op-
tion in diseases with impaired or unbalanced wound healing,
the possible interplay and mechanisms of MIF’s contribution
to the inﬂammation and migration phases certainly need fur-
ther exploration.
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